{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:16Z","timestamp":1792643836794,"version":"4.5.0"},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T00:00:00Z","timestamp":1332892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the good prognosis of pediatric mastocytosis, some patients suffer from severe mast cell (<jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content>) mediator\u2010associated symptoms. The aim of this study was to identify predictors for severe <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content> mediator release symptoms in children with mastocytosis in the skin (<jats:styled-content style=\"fixed-case\">MIS<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum baseline total tryptase (sb<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>) levels in 111 children with <jats:styled-content style=\"fixed-case\">MIS<\/jats:styled-content> \u2013 80 maculopapular cutaneous mastocytosis\/plaque mastocytosis, 22 nodular mastocytosis, and nine diffuse cutaneous mastocytosis \u2013 were investigated as a predictive biomarker for the occurrence of <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content> mediator\u2010related signs and symptoms within the first 18\u00a0months after disease onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve children (11%) who showed extensive cutaneous disease involving &gt;90% of body surface area (<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>) suffered from severe symptoms requiring hospitalization, with (<jats:italic>n<\/jats:italic>\u00a0=\u00a05) or without (<jats:italic>n<\/jats:italic>\u00a0=\u00a06) management in the intensive care unit (<jats:styled-content style=\"fixed-case\">ICU<\/jats:styled-content>) owing to life\u2010threatening complications. The median sbT was significantly (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u00a0&lt;\u00a00.001) higher in patients with extensive cutaneous disease <jats:italic>vs<\/jats:italic> those with &lt;90% of <jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content> involved (45.5 <jats:italic>vs<\/jats:italic> 5.2\u00a0\u03bcg\/l, respectively), as well as in children with grade 4 (severe mastocytosis\u2010related symptoms requiring emergency therapy and hospitalization) <jats:italic>vs<\/jats:italic> those with grade &lt;4 (46.2 <jats:italic>vs<\/jats:italic> 5.2\u00a0\u03bcg\/l, respectively). Receiver operating characteristics curve analyses showed that the optimal cutoff s for sbT to predict the need for daily antimediator therapy, hospitalization, and the management in an <jats:styled-content style=\"fixed-case\">ICU<\/jats:styled-content> were 6.6, 15.5, and 30.8\u00a0\u03bcg\/l, respectively (sensitivity and specificity of 77% and 79%, 100% and 95%, and 100% and 96%, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increased sb<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content> in association with extensive cutaneous involvement identifies patients at risk for severe <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content> activation events in pediatric mastocytosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1398-9995.2012.02812.x","type":"journal-article","created":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T12:04:51Z","timestamp":1333109091000},"page":"813-821","source":"Crossref","is-referenced-by-count":134,"title":["Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis"],"prefix":"10.1111","volume":"67","author":[{"given":"I.","family":"Alvarez\u2010Twose","sequence":"first","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) Hospital Virgen del Valle Toledo Spain"},{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Va\u00f1\u00f3\u2010Galv\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda Hospital Ram\u00f3n y Cajal Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"S\u00e1nchez\u2010Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) Hospital Virgen del Valle Toledo Spain"},{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Morgado","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) Hospital Virgen del Valle Toledo Spain"},{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matito","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) Hospital Virgen del Valle Toledo Spain"},{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torrelo","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda Hospital Ni\u00f1o Jes\u00fas Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ja\u00e9n","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda Hospital Ram\u00f3n y Cajal Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy and Immunology Virginia Commonwealth University Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orfao","sequence":"additional","affiliation":[{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"},{"name":"Servicio General de Citometr\u00eda, Centro de Investigaci\u00f3n del C\u00e1ncer\/IBMCC (USAL\/CSIC), Departamento de Medicina Universidad de Salamanca Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Escribano","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) Hospital Virgen del Valle Toledo Spain"},{"name":"Red Espa\u00f1ola de Mastocitosis (REMA) Toledo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,28]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"291","volume-title":"World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues","author":"Valent P","year":"2001"},{"key":"e_1_2_8_3_1","first-page":"54","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny HP","year":"2008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00157-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118337"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706253162603"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00020-0"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.98"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(91)90062-K"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00041-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.10072"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63870-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0575-z"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152806775269303"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/11588890-000000000-00000"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63145-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(78)80014-2"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.01.683"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3816"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.020"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.84"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01569.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.09.007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602210103"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.334"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(00)00076-5"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.4.1987"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03005.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4973"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-146852"},{"key":"e_1_2_8_34_1","article-title":"Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY\u2010HUG phase III clinical trial","author":"McGann PT","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(06)80017-5"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01533368"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.12.015"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2012.02812.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2012.02812.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:39:20Z","timestamp":1698727160000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2012.02812.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,28]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1398-9995.2012.02812.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02812.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,28]]}}}